Article
Large vessel vasculitis (LVV) and CNS vasculitis are rare subsets of vasculitis. The challenges related to these diseases are well known to the rheumatologists who treat around the world.
All News
KenWarringtonMD
Tweet
Use of diagnostic imaging for #GCA is ⬆️
Use of temporal artery biopsy⬇️
data from #MayoClinicRheumatology @garveythomasma1
#acr20 #RheumTwitter https://t.co/kQTg5FTlVq
Dr. John Cush
Tweet
HCQ Not Associated with QTc Length in SLE and RA Patients: Dr. Janet Pope @Janetbirdope #ACR20
https://t.co/zPIaFIiqr5 https://t.co/Wk8YQpIpo7
Mike Putman
Tweet
Great talk #ACR20 @anisha_dua re:monitoring in GCA/TAK
Remember different distributions in GCA/TAK
Slick summary slides with pros/cons of each modality
I find myself picking based on clinical context, suspected involvement/extent, and availability
#ACRambassador https://t.co/euMGbwirG9
Rheum Cat
Tweet
Talk on collaborative research and team building by @rheum_covid leaders @JYazdanyMD & @philipcrobinson
Dr. Yazdany with an illustration of what the journey might look like for the ECI phase & beyond
#ACR20 #ACRambassador https://t.co/ISNQSrFWws
Dr Irwin Lim
Tweet
SELECT-PsA2 group refractory to prior bDMARD therapy
UPA - useful oral JAKi option in Psoriatic Arthritis
Safety consistent with what we know from RA. More Sfx at 30mg. No clear VTE signal
#ACR20 https://t.co/XpprRprugI
Dr Philip Robinson
Tweet
Cohort study of 186 AI patients from New York => Among patients hospitalized with COVID-19, individuals with autoimmune disease did not have an increased risk of a composite outcome of intensive care unit admission, intubation, or death.
https://t.co/EXGyfrHnjH @jrheum
Peter Nash
Tweet
Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies https://t.co/itrgSeNted #RA #prednisone 18-30% flare ceasing Pred - imi for bridging rather than commence oral! Eular guidelines have a lot to answer for
Peter Nash
Tweet
Integrated Safety of Filgotinib in Patients with Moderately or Severely Active Rheumatoid Arthritis Receiving Treatment for up to 5.5 Years https://t.co/9YNEGXKoAD #RA #filgotinib low vte & low zoster rates
Peter Nash
Tweet
Safety Profile of Upadacitinib up to 3 Years of Exposure in Patients with Rheumatoid Arthritis https://t.co/T3cXYlCSRC #RA #Upadacitinib 3 yr safety data
Peter Nash
Tweet
Extreme Fatigue in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms https://t.co/sLGxMwJUhk #SLE #fatigue - fatigue remains a big problem
Dr Ai Lyn Tan
Tweet
Tender non-swollen joints NOT associated with #ultrasound synovitis in DMARD-naïve early #PsoriaticArthritis
👉🏽https://t.co/XcuhlZbpSV
by Dr Dubash @LeedsTeamSpA @LeedsBRC
#ACR20 #0313 https://t.co/TbpxIy83Qt
Peter Nash
Tweet
The Prediction of Psoriatic Arthritis Tool (PRESTO) Study – Interim Report https://t.co/zdpk6IvxP0 #PsA # predictors
Peter Nash
Tweet
Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis https://t.co/hgPDtFRxer #PsA #Guselkumab
Mrinalini Dey
Tweet
Was delighted to speak to Dr Marwan Bukhari @drdj, Editor-in-Chief of Rheumatology, yesterday at #ACR20. We discussed journal activities over the past year & his personal congress highlights. Watch the video below!
Follow the journal👉@RheumJnl
@RheumNow
https://t.co/C7WW4Ep1Sk
Janet Pope
Tweet
Consistent data that antimalarials did NOT decrease hospitalization for viral infections in the pre #COVID19 era in US claims database in SLE &RA pts #0002 @RheumNow @CRASCRRheum #ACR20 #ACR2020 https://t.co/nZp5dOeHXB
Janet Pope
Tweet
#COVID19 outcomes in systematic autoimmune diseases N=716 Pop’n matched by age & sex other COVID pts. Glass is half empty. More hospitalization, ICU, ventilation but death 5% v 4.3%. Abstr#430 #ACR20 @RheumNow @CRASCRRheum https://t.co/cqko0Igd8L
sheila
Tweet
With #ACR20 fully #virtual, what gadget will you be using to access the meeting? @RheumNow
sheila
Tweet
Dr Rubin of @NEJM on #vaccine development: safety and efficacy very important. Great keynote lecture! @RheumNow #ACR20 https://t.co/hVR2rmOMNp
sheila
Tweet
Year in review by @JYazdanyMD ENTRACTE trial: CV safety of TCZ vs. ETN >similar CV events >TCZ grp slightly more infections & GI perforations @RheumNow #ACR20 https://t.co/yBDeHBDB3Z
